Delivery Order SPE2DB20D2104-SPE2DB23FV32Z

Award Date 9/13/23
Potential Completion Date 9/14/23
Potential Value $10K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, issued by the Defense Logistics Agency (DLA), is a delivery order valued at $7,982.53 for the pharmaceutical product LINZESS 290 MCG CAPSULE UU 30S. The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. This award is part of a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC...
This federal contract award, valued at $1,587.20, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of LINZESS 290 MCG CAPSULE UU 30S, a pharmaceutical product. The award is a delivery order under an Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,247.40 Firm Fixed Price Delivery Order contract is for the supply of LINZESS 72 MCG CAPSULE UU 30S, a pharmaceutical product. The award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that Amerisourcebergen holds with the DLA Troop Support Medical, which serves as a primary vehicle...
This federal contract award, valued at $2,487.40, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order for the supply of LINZESS 290 MCG CAPSULE UU 30S, a medical product, with a completion date of May 9, 2023. The award is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at $999,999,999 and...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,102.22 firm fixed-price delivery order is for the supply of LINZESS 145 MCG CAPSULE medical products, with a period of performance through November 4, 2024. The award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical. This...
This federal contract award is for the delivery of LINZESS 145 MCG capsules to the Defense Logistics Agency (DLA). The $5,621.57 firm fixed-price delivery order was issued to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, under an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to $999,999,999.00. This single-award IDC serves as the primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical products and medical...
This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of LINZESS 290 MCG CAPSULE UU 30S, a pharmaceutical product, with a ceiling value of $3,622.62 and a period of performance through May 17, 2023. This award is a delivery order under an Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA, valued...
This federal contract award is a delivery order issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,280.72 firm fixed-price contract is for the delivery of LINZESS 145 MCG CAPSULE UU 30S, a prescription medication. The contract has an ultimate completion date of June 24, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop...
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order worth $1,615.02 with a Firm Fixed Price pricing type and an ultimate completion date of October 16, 2023. The contract is for the pharmaceutical product LINZESS 145 MCG CAPSULE UU 30S. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, provides for the delivery of LINZESS 290 MCG capsules to the Defense Logistics Agency (DLA). The $6,734.64 firm fixed price delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) the company holds with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military...
  • SPE2DB20D2104
    Indefinite Delivery Contract
  • SPE2DB20D2104-SPE2DB23FV32Z
    Delivery Order

This federal contract award is for the delivery of LINZESS 290 MCG CAPSULE UU 30S, a pharmaceutical product, to the Defense Logistics Agency (DLA). The $10,190.60 firm-fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor.

The award is associated with a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition.

Generated 2/27/25, 10:48 AM